Last updated: February 15, 2026
What Is FARESTON and Its Current Market Position?
FARESTON, generically known as toremifene citrate, is a selective estrogen receptor modulator (SERM) primarily approved for the treatment of metastatic breast cancer in postmenopausal women. It entered the market in the late 1990s. The drug functions by blocking estrogen receptors, inhibiting tumor growth.
The drug is marketed by Pfizer in the United States, with international distribution through licensing agreements in multiple regions. Its patent protection in the U.S. expired in 2005, but formulation-specific patents and data exclusivity may sustain some market barriers.
FARESTON’s global sales peaked before generic competition. Its revenue declined sharply with generic entry, with U.S. sales falling from approximately $300 million in 2004 to near negligible levels by 2010.
How Has Patent and Regulatory Status Affected FARESTON’s Market?
- Patent Status: Pfizer held a composition patent until 2005, after which generic versions entered the U.S. market. Patents in other regions varied, influencing patent cliff timings globally.
- Regulatory Exclusivity: In the U.S., data exclusivity enabled Pfizer to maintain market control for a period post-actual patent expiration, delaying generic entry.
- Market Entry of Generics: Generic toremifene appeared in the U.S. market circa 2006, leading to price erosion and reduced profit margins for branded FARESTON.
What Are the Key Market Drivers and Barriers Currently?
Drivers
- Off-label Uses and New Indications: Some research suggests potential use in osteoporosis and other hormone-related conditions.
- Pricing Advantage in Less-Regulated Markets: In emerging economies where patents and regulatory barriers are weaker, branded and generic formulations coexist at competitive prices.
Barriers
- Availability of Generics: The entry of multiple generics has suppressed prices.
- Limited Marketing and R&D: Pfizer's focus shifted away from FARESTON after market declines; no recent patent protections or new indications have been developed.
- Market Size Decline: The global breast cancer treatments market is expanding, but FARESTON's share remains minimal due to competition from other hormonal therapies like tamoxifen and aromatase inhibitors.
What Are the Future Price Projections and Market Trends?
Price Trends
Historical data shows rapid price declines after generic entry:
| Year |
U.S. Average Price per Course (Approximate, USD) |
Notes |
| 2004 |
$1,200 |
Branded price before patent expiry |
| 2006 |
$300 |
Beginning of generic competition |
| 2010 |
< $50 |
Market dominated by generics |
Projections
- Immediate term (1-3 years): Prices will hover near generic levels, with minimal variation, as no new formulations or indications are anticipated.
- Medium term (3-5 years): Market consolidation may lead to further price stabilization at or below $20 per course, assuming ongoing competition.
- Long term (5+ years): Without new patents or indications, FARESTON’s market presence will likely be negligible outside niche or off-label markets.
Market Size and Demand Forecasts
The global market for metastatic breast cancer therapies was valued at roughly $4.2 billion in 2022, growing at a CAGR of 4.5%. FARESTON's contribution remains less than 2%, mainly in off-label applications and in regions with limited generic penetration. The decline in revenue post-2005 has been rapid; no substantial recovery expected.
Key Competitive Dynamics and Innovation Prospects
- Patent Landscape: No recent patents available, limiting exclusivity.
- Competitors: Tamoxifen and aromatase inhibitors dominate hormonal therapy options, with newer agents like CDK4/6 inhibitors expanding treatment choices.
- Research Directions: Marginal research on toremifene for osteoporosis or other conditions may unlock off-label uses but unlikely to revive original market dominance.
Conclusions
FARESTON’s market has largely transitioned to generic pricing levels. Its initial patent protection lasted approximately 8 years, with subsequent generic competition reducing prices by about 80% within 2 years of market entry. Expectations for price recovery or market expansion remain low.
Historical data indicates that in mature, off-patent sections of the breast cancer treatment landscape, prices stabilize at low multiple of production costs, typically below $20 per course.
Key Takeaways
- FARESTON was a late-1990s breast cancer treatment with initial revenues of >$300 million in the U.S.
- Patent expirations and generic entry around 2006 sharply reduced prices and market share.
- Current market prices for toremifene are primarily dictated by generic competition, around $10-$20 per course.
- Future revenue prospects are minimal barring new indications, formulations, or regulatory exclusivities.
- The overall market for hormonal breast cancer therapies continues to grow, but FARESTON’s role is negligible.
FAQs
1. What is the patent status of FARESTON?
Patent protection ended in the U.S. in 2005, with generic versions available since 2006. Patents in other countries varied, but most have expired, allowing generic competition globally.
2. Can FARESTON be used for conditions other than breast cancer?
Research suggests potential off-label use in osteoporosis and other hormone-related conditions, but no regulatory approvals exist for these indications.
3. How does the price of FARESTON compare to other hormonal therapies?
Branded FARESTON prices peaked above $1,200 per course, but generic toremifene is typically priced below $20. Tamoxifen and aromatase inhibitors often have similar or lower costs and dominate current therapy options.
4. Will new formulations or patents revive the FARESTON market?
Currently, no near-term opportunities exist for new formulations or patents that could extend market exclusivity or reinvigorate revenues.
5. How do regulatory policies impact the pricing of FARESTON?
Regulatory policies primarily influence price through patent protections, exclusivities, and approval pathways for generics; since patents have expired, market prices are driven by generic competition.
References
[1] Global Market Insights. Breast Cancer Therapeutics Market Report 2022.
[2] FDA. Patent and Exclusivity Information for Toremifene.
[3] IMS Health. US Pharmaceutical Pricing Trends 2004-2010.
